Over the last few years, there has been a renewed interest in patients with characteristics of both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is still controversial, patients with overlapping features are frequently encountered in clinical practice, and may indeed have worse clinical outcomes and increased health-care utilization than those with asthma or COPD. Therefore, there is a critical need to set a framework for the therapeutic approach of such patients. There are key distinctions in the therapy between asthma and COPD, particularly regarding the initial choice of therapy. However, there is considerable overlap in the use of existing medications for both diseases. Furthermore, novel therapies approved for asthma, such as monoclonal antibodies, may have a role in patients with COPD and ACO. The use of biomarkers, such as peripheral blood eosinophils, exhaled nitric oxide, and serum IgE, may help in selecting appropriate therapies for ACO. In this review, we provide an overview of available treatments for both asthma and COPD and explore their potential role in the treatment of patients with ACO.
There is considerable debate on how to precisely define ACO. 6 The key points of controversy on the utility of defining ACO include (1) the various definitions assume that patients that have features of both asthma and COPD represent a homogenous group, (2) each disease has a different mechanism and probably is composed of multiple endotypes with diverse disease manifestations, (3) the definitions lack assignment of how much weight each disease has on the clinical manifestations and outcomes, and (4) the definitions are sensitive but lack specificity. 6, 7 Furthermore, most clinical trials of asthma and of COPD have excluded patients with overlapping features, which limits our understanding of patients who have characteristics of both diseases. 7 Definitions that have been previously used to describe ACO include the presence of a postbronchodilator FEV 1 /FVC < 0.7 in addition to various combinations of clinical features, including significant history of smoking, patientreported diagnosis of asthma, physician's diagnosis of asthma, postbronchodilator increase of FEV 1 > 200 to 400 mL or 12% to 15% predicted, blood or sputum eosinophilia, and history of wheezing. [8] [9] [10] [11] A round table discussion by Sin et al, 7 taking into consideration all aspects of both disease and published literature, reached a consensus definition that included major and minor criteria (Table 1 ). This definition of ACO will likely require further revision as the complexity of this entity is better understood.
Despite the many definitions, patients who meet criteria or are considered within the spectrum of ACO may have worse outcomes than those with either disease alone. Patients with ACO have more respiratory symptoms, greater physical impairment, worse quality of life, and a higher risk for exacerbations and hospitalizations. [12] [13] [14] Furthermore, patients with ACO may have more health-care utilization and cost of care than those with a single disease. 5, 9, [12] [13] [14] The reasons for these observations are incompletely understood. It is possible that both diseases comprise a continuum of a single disease as described by Orie and Sluiter in the Dutch hypothesis 15 Inhaled medications are the foundation of therapy for both asthma and COPD. The treatment of these diseases uses a stepwise or escalation approach based on symptoms and exacerbations. 22, 23 However, there is a key distinction between both treatment algorithms: specifically, the introduction of inhaled corticosteroids (ICSs) (Fig 1) . In asthma, ICSs are introduced early in the treatment for patients who are symptomatic. ICSs decrease the risk of severe exacerbations, improve asthma control, and reduce the loss of lung function over time in patients with mild asthma. 24, 25 Moreover, patients with asthma who stop ICSs have a higher risk of future exacerbations than those who continue therapy.
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A long-acting b 2 agonist (LABA) is recommended as an add-on medication to ICSs only after ICSs and/or other controllers are ineffective in achieving adequate asthma control. 23 LABAs are contraindicated for use as a single agent in asthma because of safety concerns because two large clinical trials have findings that link the use of salmeterol to increased rates of asthma-related deaths. 27, 28 Although combination therapy (ICS/LABA) was found to be equally safe compared with ICSs alone in patients with persistent asthma and a history of severe exacerbations, there is still controversy related to the potential risk of LABAs in subsets of patients. 29 A LABA and/or LAMA is the preferred initial therapy in COPD, whereas the addition of ICSs is reserved for later stages in treatment (Fig 1) . The use of long-acting bronchodilators (LABA or LAMA) alone in COPD has been shown to improve lung function, symptoms, and quality of life and reduce rates of exacerbations and hospitalizations. [30] [31] [32] LABA monotherapy is generally considered safer in COPD than in asthma. 30 LAMAs can also be used as a single agent and have been shown to be superior to LABAs in the reduction of exacerbations rates. 33 However, the overall safety of bronchodilators in COPD is controversial, particularly regarding cardiovascular side effects. [34] [35] [36] [37] Close monitoring may be warranted in patients with severe cardiovascular disease or life-threatening cardiovascular events because these were excluded from prior trials. chestjournal.org hyperresponsiveness, most experts advocate that bronchodilators should be continued with the addition of ICSs. 19, 46 In addition to inhaled therapy, the clinician should address nonpharmacologic measures for both diseases including appropriate inhaler technique, identification and avoidance of triggers, smoking cessation, vaccination, pulmonary rehabilitation, oxygen therapy, and others. 19, 22, 23 There is still much to be learned about the therapy of ACO in the milder stages, and the listed recommendations are based on expert opinion. 19, 46 Contrasting Therapies of Asthma and COPD in Severe Disease
Both severe asthma and COPD are characterized by worsening respiratory symptoms, frequent exacerbations and increased health-care utilization. 47, 48 In these advanced stages, the treatment may require triple therapy with ICS, LABA, and LAMA (Fig 1) . In COPD, triple therapy has been shown to improve lung function and exacerbation rates without increasing adverse events compared with dual therapy and placebo. [49] [50] [51] For instance, a recent study by Vestbo et al 52 showed that triple therapy decreased the rate of moderate-to-severe COPD exacerbations by 20% compared with tiotropium alone without increasing the risk of pneumonia. Similarly, improvements in lung function and exacerbations rates have been observed with the addition of tiotropium to the combination of ICS and LABA in asthma. 16, 53 A study by Magnussen et al 54 showed in patients with COPD, concomitant asthma, and at least 1 year of ICS therapy, that tiotropium was superior compared with placebo in improving pulmonary function and reducing the need for rescue albuterol after 12 weeks of therapy. It is reasonable for patients with ACO who remain symptomatic or with frequent exacerbations despite initial inhaler therapy to be treated with triple therapy, but future studies are required to validate this measure. Only tiotropium has been well studied in asthma, and it remains unclear if all LAMAs are equally effective in the therapy of this patient population.
Monoclonal Antibodies
Monoclonal antibodies against IgE and IL-5 have been effective in reducing asthma exacerbations, ED visits, and oral corticosteroids in patients with severe allergic and eosinophilic disease, respectively. 55, 56 Responder populations can be identified on the basis of type 2 inflammation phenotypes such as elevated peripheral blood eosinophils or elevated fractional exhaled nitric oxide. It is possible that these therapies could be of benefit for individuals with ACO. Recent data suggest that some individuals with ACO may also share similar disease drivers as type 2 inflammation in patients with asthma. 57 This approach was explored in a trial of omalizumab (anti-IgE) in patients with severe allergic asthma and overlapping features of COPD. 58 In the ACO subgroup, omalizumab was equally effective in improving asthma control and health-related quality of life compared with patients with severe allergic asthma alone. 58 Additionally, an open-label, real-world study designed to evaluate predictors of clinical effectiveness in response to omalizumab in a cohort of asthmatics described the positive effects of this therapy in patients with overlapping features of asthma and COPD. 59 The subgroup of patients with ACO experienced significant improvements in exacerbation rates after initiation of therapy compared with 12 months prior (mean, 1.1 vs 3.6). These patients also experienced improvements in asthma control. 59 Supporting this concept, a prespecified subgroup analysis demonstrated that patients with COPD with an eosinophilic phenotype had a trend toward improvements in symptoms scores and exacerbations with the use of anti-IL-5 receptor antibody benralizumab, warranting further study in this COPD phenotype. 60 More recently, mepolizumab, another anti-IL-5 antibody, showed a decrease in moderate or severe exacerbations in patients with COPD and an eosinophilic phenotype compared with placebo. 61 Ongoing studies will further clarify the role of these and other monoclonal antibodies in ACO, but evidence continues to emerge pointing toward the benefits of these therapies in this subgroup of patients.
Phosphodiesterase Inhibitors
Roflumilast, an oral phosphodiesterase-4 inhibitor, has been shown to improve lung function and exacerbation rates in patients with COPD and FEV 1 < 50% predicted, chronic bronchitis, and history of frequent or severe exacerbations. 62, 63 Roflumilast has also been studied in various asthma populations. An analysis of nine placebo-controlled, double-blind, parallel group phase II or III studies (985 sites across all continents) evaluating the effects of roflumilast in patients with a history of asthma was conducted. 64 Of these studies, four phase III monotherapy studies and two phase III combination (with ICS) studies consistently revealed statistically significant improvements in lung function in patients with asthma. The roflumilast dose of 500 mg generally showed more improvement in FEV 1 compared with 125 or 250 mg. More recently, a study showed that roflumilast improved lung function and asthma control in patients with moderate-to-severe asthma. 65 Importantly, roflumilast has been shown to have an adequate safety profile in asthma. 65, 66 Although no trials exist to date evaluating the use of roflumilast in patients with ACO, this therapy could be considered, particularly among those individuals with ACO with frequent exacerbations.
Macrolides
The use of macrolides has been explored in various pulmonary diseases. Chronic azithromycin has been linked to a reduction in exacerbations rates among individuals with COPD and is currently recommended for those with frequent exacerbations who are not actively smoking (Fig 1) . 22, 67, 68 On the other hand, the use of macrolides for chronic asthma has had mixed results. A double-blind, placebo-controlled trial evaluating the use of 26 weeks of azithromycin did not find any significant benefits in severe asthma exacerbation rates or lower respiratory tract infections. 69 In the same study, among those patients with a noneosinophilic inflammatory profile and a fractional exhaled nitric oxide below the upper limit of normal, the use of azithromycin was associated with lower rates of exacerbations. Similar observations, in which macrolides had beneficial effects among patients with severe asthma without eosinophilia, had previously been reported. 70 Despite these promising findings, a rigorous systematic review of 23 studies performed to determine the efficacy of macrolides in asthma concluded there was no beneficial effect compared with placebo, but these studies had significant heterogeneity and varying study designs and sample sizes. 71 More recently, a study of 420 patients with symptomatic asthma despite ICS/LABA showed that azithromycin 500 mg three times weekly for 48 weeks reduced asthma exacerbations and improved asthma-related quality of life compared with placebo. 72 Notably, reductions were seen in both eosinophilic and noneosinophilic phenotypes. Therefore, in patients with ACO, macrolides can be considered for those patients with frequent exacerbations given the evidence in COPD and increased evidenced of benefits in asthma. Future studies, with predefined ACO populations, are still needed to determine the role of macrolides in this setting.
Role of Biomarkers in ACO
The use of biomarkers to identify patients who may benefit from therapy is well established in asthma. 55, 56 In COPD, this method has accumulating evidence of benefits. 60, 61 Although this approach might appear to be particularly useful to identify the ACO population, to date there is no biomarker that best encompasses the biologic mechanisms of this overlap. In fact, evidence suggests that ACO is a heterogeneous group encompassing several phenotypes of disease, including both eosinophilic and neutrophilic immune activation. For example, sputum analysis has demonstrated both eosinophilic and neutrophilic groups within ACO cohorts. 16 Even exacerbations in ACO appear to express different biologic clusters. 73 Taken into consideration this heterogeneity, it has been suggested that the use of sputum cellularity can identify three distinct ACO subtypes: eosinophilic, neutrophilic, and paucigranulocytic. 74 However, this strategy may be limited because the use of sputum analysis has not been widely used in clinical practice because of the high technical demands of this test. Despite these limitations, the use of biomarkers for type 2 inflammation may better categorize patients with ACO than the traditional clinical taxonomy. 75 More recently, airway epithelial genomic signatures were used to identify a subgroup of patients with COPD who may have type 2 inflammation active disease using various COPD cohorts. 57 Using this method, it was possible to identify a subgroup of patients with greater airway obstruction and bronchodilator reversibility and increased airway tissue and blood eosinophils. 57 Importantly, this group also had a decrease in hyperinflation after treatment with ICSs, suggesting an improvement in small airway inflammation.
Although not yet widely available, the use of type 2 inflammation genomic signatures may serve as predictors of response to therapy in patients with ACO.
Along with ACO, there has been renewed attention to eosinophilic COPD. 60, 61 Up to 20% to 40% of individuals with COPD may have increased eosinophils in the sputum and blood. 76, 77 There is some evidence to suggest that a subset of individuals with ACO may have neutrophilic inflammation driving their disease. However, the benefit of non-type 2 inflammation therapies has yet to be studied in this population. Neutrophilic inflammation can be seen in both COPD and asthma, and neutrophilic inflammation may be more frequently encountered in severe asthma. 87 Therefore, targeting this inflammatory pathway is an attractive therapeutic strategy in ACO for future studies. 74 Therapeutic Guidance
In patients with ACO who remain symptomatic despite inhaled therapies, an in-depth evaluation is required to determine the presence of treatable traits, which may aid in the diagnosis and provide therapeutic guidance. 46 Further work is needed to help clinicians select the most appropriate therapy. Predictors of response in chronic airways disease is an area of intense research. Elevated serum levels of IgE, exhaled fraction of nitric oxide, and peripheral blood eosinophilia not only provide potential insight to the ongoing pathologic processes, but also may predict response to certain therapies, such as omalizumab. 88 Future therapies that emphasize biomarker or mechanistic approaches rather than clinical features to segment patient populations may better determine responder populations.
Conclusions
There is still much to learn about the spectrum of ACO. Because asthma and COPD are inherently heterogeneous, future studies that include wellcharacterized and richly phenotyped cohorts of patients with features of both asthma and COPD, with varying degrees of severity and exacerbation history, are needed to better study disease interactions, risk factors, and prognostic makers. 89 A gap clearly exists in the evidence for therapy in ACO, particularly in severe disease. Nevertheless, in clinical practice, patients with ACO, with varying features of asthma and COPD features, present frequently and require optimal therapy. Taking into consideration that two diseases may coexist, with an emphasis in safety and phenotyping, it is necessary to carefully select therapies on a case-by-case basis.
Identifying the presence of ACO in a clinic patient is the first step toward developing a treatment plan. However, it remains necessary to develop individualized plans based on concurrent evidence from clinical and biomarker data. Future studies that connect disease phenotypes to targeted therapies may identify improved personalized approaches to all patients with COPD or asthma.
